Literature DB >> 25977176

Evaluation of effect of self-examination and physical examination on breast cancer.

Lotfi Mohammad Hassan1, Noori Mahmoud2, Anthony B Miller3, Harrirchi Iraj4, Mirzaei Mohsen5, Jafarizadea Majid5, Sadeghian Mohammad Reza5, Minosepehr Mojgan5.   

Abstract

BACKGROUND: Breast cancer is the number one cancer of women in the world. More than 90% of breast cancers can be cured with early diagnosis followed by effective multimodality treatment. The efficacy of screening by breast self-examination (BSE) and breast physical examination (BPx) is best evaluated using randomized screening trials.
METHOD: A total of 12,660 women aged 35-64 years, 6330 in the intervention group and 6330 in the control group, were randomly selected from four areas of Yazd city, I.R. of Iran. The number of detected cancers along with kind of cancer, staging of cancer, the route of detected cancer and the number of deaths during the first 5 years of the study were collected and analyzed.
RESULTS: No significance difference between the two groups was seen in respect to socio-demographic and socio-economic variables (P > 0.05). Subjects in the intervention group had a response rate of 83.5% for attending the health center and 80.2% for visiting the assigned surgeon. A total of 31 and 13 new cases of breast cancer were identified in the intervention and control groups, respectively, of which 48.5% of cases in the intervention group were <50 yr of age. A significant difference between the cumulative incidence of breast cancer in the two groups with a ratio of 2.4 was observed.
CONCLUSION: BSE &amp; BPx have a significant effect in detecting breast cancers at early stages (<3) suggesting they are effective screening tests with high availability and low costs that can be applied at the community level.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Breast cancer; Breast physical examination; Breast self-examination; Cancer detection; Randomized screening trial; Yazd and Iran

Mesh:

Year:  2015        PMID: 25977176     DOI: 10.1016/j.breast.2015.04.011

Source DB:  PubMed          Journal:  Breast        ISSN: 0960-9776            Impact factor:   4.380


  6 in total

1.  Plasma phospholipase A2 activity may serve as a novel diagnostic biomarker for the diagnosis of breast cancer.

Authors:  Jingkun Qu; Xixi Zhao; Jizhao Wang; Chao Liu; Yuchen Sun; Hui Cai; Jianlin Liu
Journal:  Oncol Lett       Date:  2018-01-31       Impact factor: 2.967

2.  Diagnostic Accuracy of Breast Medical Tactile Examiners (MTEs): A Prospective Pilot Study.

Authors:  Michael P Lux; Julius Emons; Mayada R Bani; Marius Wunderle; Charlotte Sell; Caroline Preuss; Claudia Rauh; Sebastian M Jud; Felix Heindl; Hanna Langemann; Thomas Geyer; Anna-Lisa Brandl; Carolin C Hack; Werner Adler; Rüdiger Schulz-Wendtland; Matthias W Beckmann; Peter A Fasching; Paul Gass
Journal:  Breast Care (Basel)       Date:  2019-01-30       Impact factor: 2.860

3.  Mapping evidence on women's knowledge and practice of breast self-examination in sub-Saharan Africa: a scoping review protocol.

Authors:  Roseline H Udoh; Monica Ansu-Mensah; Mohammed Tahiru; Vitalis Bawontuo; Desmond Kuupiel
Journal:  Syst Rev       Date:  2020-01-06

Review 4.  Women's knowledge, attitude, and practice of breast self- examination in sub-Saharan Africa: a scoping review.

Authors:  Roseline H Udoh; Mohammed Tahiru; Monica Ansu-Mensah; Vitalis Bawontuo; Frederick Inkum Danquah; Desmond Kuupiel
Journal:  Arch Public Health       Date:  2020-09-22

5.  Breast cancer screening knowledge among Hungarian women: a cross-sectional study.

Authors:  Diána Reményi Kissné; Noémi Gede; Zsolt Szakács; István Kiss
Journal:  BMC Womens Health       Date:  2021-02-15       Impact factor: 2.809

6.  Long noncoding RNA CCAT2 reduces chemosensitivity to 5-fluorouracil in breast cancer cells by activating the mTOR axis.

Authors:  Daoping Zhou; Juan Gu; Yueping Wang; Bing Luo; Mei Feng; Xuedong Wang
Journal:  J Cell Mol Med       Date:  2022-02-15       Impact factor: 5.310

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.